{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:21:40Z","timestamp":1790803300732,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] is an inherited cardiovascular risk factor. However, its association with coronary plaque characteristics beyond traditional risk enhancers remains unclear. We aimed to evaluate the association between Lp(a) levels and coronary plaque characteristics in asymptomatic primary prevention patients, and to compare its predictive value against other risk enhancers, including LDL particle concentration (LDL-P), high-sensitivity C-reactive protein (hsCRP), and coronary artery calcium (CAC) score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We retrospectively analysed 547 asymptomatic patients undergoing coronary computed tomography angiography (CCTA) between 2018 and 2024. Plaque characteristics were assessed using artificial intelligence-based quantitative CCTA. Associations between Lp(a), LDL-P, hsCRP, CAC score, and plaque features were evaluated using multivariable regression adjusted for age and sex. Median age was 56 years, 69.8% were male. Higher Lp(a) was associated with greater total plaque volume (\u03b2=23.1\u2005mm\u00b3, P = 0.006), calcified plaque (\u03b2=11.1\u2005mm\u00b3, P = 0.014), non-calcified plaque (\u03b2=12.0\u2005mm\u00b3, P = 0.027), and low-density non-calcified plaque (LDNCP; \u03b2=0.4\u2005mm\u00b3, P &amp;lt; 0.001) volumes, as well as increased area stenosis (\u03b2=1.9%, P = 0.031) and remodelling index (\u03b2=0.02, P = 0.017). In multivariable models, CAC score was the strongest predictor of overall plaque burden, including calcified and non-calcified plaque (P &amp;lt; 0.000), but was not associated with LDNCP. Lp(a) remained independently associated with LDNCP (\u03b2=0.45\u2005mm\u00b3, P = 0.013), while LDL-P and hsCRP showed no significant associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In asymptomatic primary prevention patients, Lp(a) was independently associated with high-risk coronary plaque features, specifically LDNCP, beyond traditional risk enhancers. These findings highlight the unique role of Lp(a) in identifying coronary plaque vulnerability and suggest complementary roles for Lp(a) and CAC in refining cardiovascular risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjci\/jeag024","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:39:39Z","timestamp":1769171979000},"page":"1012-1021","source":"Crossref","is-referenced-by-count":5,"title":["Lipoprotein(a) selectively associates with vulnerable coronary plaque phenotypes in comparison with other established risk markers"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9884-9752","authenticated-orcid":false,"given":"Rebecca","family":"Fisher","sequence":"first","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-6669","authenticated-orcid":false,"given":"Chen","family":"Gurevitz","sequence":"additional","affiliation":[{"name":"Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital , 1428 Madison Avenue, Atran | 8th Floor, New York, NY 10029 ,","place":["USA"]},{"name":"Cardiology Division, Rabin Medical Center, Petah-Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A","family":"Fisher","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisuk","family":"Park","sequence":"additional","affiliation":[{"name":"Cleerly Inc. , Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Aquino","sequence":"additional","affiliation":[{"name":"Cleerly Inc. , Denver, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha N","family":"Goonewardena","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Michigan , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S","family":"Rosenson","sequence":"additional","affiliation":[{"name":"Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital , 1428 Madison Avenue, Atran | 8th Floor, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026042919565145100_jeag024-B1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B2","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026042919565145100_jeag024-B3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026042919565145100_jeag024-B4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042919565145100_jeag024-B5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026042919565145100_jeag024-B6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026042919565145100_jeag024-B7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2018.10.066","article-title":"Coronary artery plaque characteristics associated with adverse outcomes in the SCOT-HEART study","volume":"73","author":"Williams","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026042919565145100_jeag024-B8","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/eurjpc\/zwae007","article-title":"Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity","volume":"31","author":"Leistner","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026042919565145100_jeag024-B9","doi-asserted-by":"crossref","first-page":"e018023","DOI":"10.1161\/JAHA.120.018023","article-title":"Association of serum lipoprotein (a) levels and coronary atheroma volume by intravascular ultrasound","volume":"9","author":"Huded","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026042919565145100_jeag024-B10","first-page":"101120","article-title":"Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome","volume":"43","author":"Kato","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026042919565145100_jeag024-B11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.01.020","article-title":"Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease","volume":"246","author":"Niccoli","year":"2016","journal-title":"Atherosclerosis"},{"key":"2026042919565145100_jeag024-B12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026042919565145100_jeag024-B13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0735-1097(25)00876-9","article-title":"Lipoprotein (a) and coronary atherosclerosis in intracoronary imaging\u2014the YELLOW-lp(a) study","volume":"85","author":"Gurevitz","year":"2025","journal-title":"JACC"},{"key":"2026042919565145100_jeag024-B14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacl.2018.03.090","article-title":"Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease","volume":"12","author":"Chieng","year":"2018","journal-title":"J Clin Lipidol"},{"key":"2026042919565145100_jeag024-B15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jcmg.2020.08.025","article-title":"CT angiographic and plaque predictors of functionally significant coronary disease and outcome using machine learning","volume":"14","author":"Yang","year":"2021","journal-title":"J Am Coll Cardiol Img"},{"key":"2026042919565145100_jeag024-B16","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/eurheartj\/ehad867","article-title":"C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project","volume":"45","author":"Arnold","year":"2024","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026042919565145100_jeag024-B19","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines [published correction appears in circulation. 2019;139(25):e1182-e1186] [published correction appears in circulation. 2023;148(7):e5]","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2026042919565145100_jeag024-B20","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B21","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B22","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/CIRCULATIONAHA.122.060308","article-title":"Noninvasive plaque imaging to accelerate coronary artery disease drug development","volume":"146","author":"Figtree","year":"2022","journal-title":"Circulation"},{"key":"2026042919565145100_jeag024-B23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jacl.2011.07.001","article-title":"Low-density lipoprotein particle number predicts coronary artery calcification in asymptomatic adults at intermediate risk of cardiovascular disease","volume":"5","author":"Prado","year":"2011","journal-title":"J Clin Lipidol"},{"key":"2026042919565145100_jeag024-B24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10557-022-07407-y","article-title":"Quantification of LDL-cholesterol corrected for molar concentration of lipoprotein(a)","volume":"38","author":"Rosenson","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026042919565145100_jeag024-B25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcmg.2021.10.020","article-title":"AI evaluation of stenosis on coronary CTA, comparison with quantitative coronary angiography and fractional flow reserve: a CREDENCE trial substudy","volume":"16","author":"Griffin","year":"2023","journal-title":"J Am Coll Cardiol Img"},{"key":"2026042919565145100_jeag024-B26","doi-asserted-by":"crossref","first-page":"e001832","DOI":"10.1136\/openhrt-2021-001832","article-title":"Relationship of age, atherosclerosis and angiographic stenosis using artificial intelligence","volume":"8","author":"Jonas","year":"2021","journal-title":"Open Heart"},{"key":"2026042919565145100_jeag024-B27","doi-asserted-by":"crossref","first-page":"117363","DOI":"10.1016\/j.atherosclerosis.2023.117363","article-title":"Determination of lipid-rich plaque by artificial intelligence-enabled quantitative computed tomography using near-infrared spectroscopy","volume":"386","author":"Omori","year":"2023","journal-title":"Atherosclerosis"},{"key":"2026042919565145100_jeag024-B28","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jcct.2014.07.003","article-title":"SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the society of cardiovascular computed tomography guidelines committee","volume":"8","author":"Leipsic","year":"2014","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2026042919565145100_jeag024-B29","doi-asserted-by":"crossref","first-page":"e220183","DOI":"10.1148\/ryct.220183","article-title":"CAD-RADS\u2122 2.0\u20142022 coronary artery disease\u2014reporting and data system an expert consensus document of the society of cardiovascular computed tomography (SCCT), the American College of Cardiology (ACC), the American college of radiology (ACR) and the North America society of cardiovascular imaging (NASCI)","volume":"4","author":"Cury","year":"2022","journal-title":"Radiol Cardiothorac Imaging"},{"key":"2026042919565145100_jeag024-B30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcct.2020.11.002","article-title":"Society of cardiovascular computed tomography\/North American society of cardiovascular imaging\u2014expert consensus document on coronary CT imaging of atherosclerotic plaque","volume":"15","author":"Shaw","year":"2021","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2026042919565145100_jeag024-B31","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"2026042919565145100_jeag024-B32","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/ehjci\/jeab292","article-title":"Clinical applications of cardiac computed tomography: a consensus paper of the European association of cardiovascular imaging\u2014part II","volume":"23","author":"Pontone","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026042919565145100_jeag024-B33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamacardio.2017.4973","article-title":"Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: a secondary analysis of the PROMISE randomized clinical trial","volume":"3","author":"Ferencik","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026042919565145100_jeag024-B34","doi-asserted-by":"crossref","first-page":"e000096","DOI":"10.1136\/openhrt-2014-000096","article-title":"The diagnostic and prognostic value of coronary CT angiography in asymptomatic high-risk patients: a cohort study","volume":"1","author":"Plank","year":"2014","journal-title":"Open Heart"},{"key":"2026042919565145100_jeag024-B35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jcct.2021.05.004","article-title":"CT evaluation by artificial intelligence for atherosclerosis, stenosis and vascular morphology (CLARIFY): a multi-center, international study","volume":"15","author":"Choi","year":"2021","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2026042919565145100_jeag024-B36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","volume":"9","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026042919565145100_jeag024-B37","doi-asserted-by":"crossref","first-page":"ehad655.2503","DOI":"10.1093\/eurheartj\/ehad655.2503","article-title":"Characterization of lipidic coronary atheroma under control of low-density lipoprotein&lt;1.8\u2005mmol\/L and lipoprotein (a) &lt;50\u2005mg\/dL in patients with coronary artery disease","volume":"44","author":"Shishikura","year":"2023","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B38","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jacc.2024.03.367","article-title":"Association of lipoprotein(a) levels with myocardial infarction in patients with low-attenuation plaque","volume":"83","author":"Yu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026042919565145100_jeag024-B39","doi-asserted-by":"crossref","first-page":"e016152","DOI":"10.1161\/CIRCIMAGING.123.016152","article-title":"Lipoprotein(a) and coronary plaque in asymptomatic individuals: the Miami heart study at baptist health south Florida","volume":"17","author":"Mszar","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026042919565145100_jeag024-B40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2025.04.013","article-title":"Lipoprotein(a), cholesterol, triglyceride levels, and vulnerable coronary plaques: a PROSPECT II substudy","volume":"85","author":"Erlinge","year":"2025","journal-title":"JACC"},{"key":"2026042919565145100_jeag024-B41","doi-asserted-by":"crossref","first-page":"e0289111","DOI":"10.1371\/journal.pone.0289111","article-title":"Long-term statin therapy is associated with severe coronary artery calcification","volume":"18","author":"Ngamdu","year":"2023","journal-title":"PLoS One"},{"key":"2026042919565145100_jeag024-B42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41514-018-0026-2","article-title":"The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy","volume":"4","author":"Ikegami","year":"2018","journal-title":"NPJ Aging Mech Dis"},{"key":"2026042919565145100_jeag024-B43","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/eurjpc\/zwad122","article-title":"Biomarker-based prediction of fatal and non-fatal cardiovascular outcomes in individuals with diabetes mellitus","volume":"30","author":"Haller","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2026042919565145100_jeag024-B44","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.1038\/s41598-023-39051-3","article-title":"Association between high-sensitivity C-reactive protein and coronary atherosclerosis in a general middle-aged population","volume":"13","author":"Cederstr\u00f6m","year":"2023","journal-title":"Sci Rep"},{"key":"2026042919565145100_jeag024-B45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in eur heart J. 2020;41(44):4255]","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026042919565145100_jeag024-B46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association [published correction appears in J clin lipidol. 2022 sep-oct;16(5):e77-e95]","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2026042919565145100_jeag024-B47","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042919565145100_jeag024-B48","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/advance-article-pdf\/doi\/10.1093\/ehjci\/jeag024\/66602198\/jeag024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/5\/1012\/66602198\/jeag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article-pdf\/27\/5\/1012\/66602198\/jeag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:57:07Z","timestamp":1777507027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcimaging\/article\/27\/5\/1012\/8442857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjci\/jeag024","relation":{},"ISSN":["2047-2404","2047-2412"],"issn-type":[{"value":"2047-2404","type":"print"},{"value":"2047-2412","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,28]]}}}